Weight Loss Drugs Significantly Reduce COVID-19 Mortality

Semaglutide, the active ingredient in Ozempic and Wegovy, shows a 33% reduction in coronavirus-related deaths among users.

Research led by Brigham and Women's Hospital observed over 17,600 participants with cardiovascular disease and obesity.
Participants on semaglutide had lower rates of all-cause mortality, including from cardiovascular and infectious diseases.
The study spanned over three years, capturing data before and during the COVID-19 pandemic.
Semaglutide also demonstrated benefits in managing heart failure, inflammation, and chronic kidney disease.
Further research is needed to fully understand the broad health impacts of semaglutide.